Ixico to assist late phase Huntington's disease study

Ixico on Tuesday reported that it has been confirmed as the provider of data analytics and neuroimaging services to support the ongoing treatment of participants in a late phase clinical research programme into Huntington's disease.

A statement from the company, which focuses on delivering insights in neuroscience, said that the agreement will generate additional revenues of £0.5m for Ixico during the course of the study.

The AIM traded company said its offering and expertise will be employed in an extension study to allow people living with the disease to continue to contribute to the search for a treatment for this condition, which is an inherited disorder that results in death of brain cells and affects mood, coordination and mental abilities.

Giulio Cerroni, chief executive of Ixico, said: "We are pleased to announce our involvement in this late phase clinical study, which supports the search for an effective treatment of Huntington's disease. The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development."

Ixico's shares were down 3.28% at 29.50p at 1343 GMT.